Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMOX vs Simplified GEMOX in Metastatic Pancreatic Cancer
NCT00268411Phase 3Unknown
- Sponsor
- GERCOR
- Start
- Sep 2004
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised trial of gemcitabine and oxaliplatin in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by GERCOR. Primary endpoint: Objective Response Rate. Status: unknown.
02
Drugs
gemcitabineoxaliplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00268411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00268411.